Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds - 2Collierville residents with no power as temperatures plunge
- 3Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- 4The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 5Figure out How to Track and Anticipate Future Cd Rates
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- Understanding Preschool Projects: An Extensive Aide
- UN chief calls on Yemen's Houthi rebels to free all UN detainees
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- December’s full moon is the last supermoon of the year. Here’s what to know
- 4 Energy-Proficient Clothes washers to Consider in 2024
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
